

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


The Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/757,962
				Filing Date	January 14, 2004
				First Named Inventor	Mohammad R. Marzabadi
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	20082/1200795-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
CE	AA	US-5,541,326-B1	07-30-1996	Cliffe	
CE	AB	US-6,503,928-B1	01-07-2003	Kelly et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>4</sup> -Number <sup>5</sup> -Kind Code <sup>6</sup> (if known)				
u	BA	WO-2004/005257-A1	01-15-2004	Synaptic Pharmaceutical Corporation		
	BB	WO-03/004027-A1	01-16-2003	Synaptic Pharmaceutical Corporation		
	BC	WO-02/094799-A2	11-29-2002	Neurogen Corporation		
	BD	WO-99/10316-A1	03-04-1999	Kissei Pharmaceutical Co., Ltd.		
	BE	WO-97/28140-A1	08-07-1997	Pierre Fabre Medicament		
	BF	WO-00/54772-A1	09-21-2000	Aventis Pharma S.A.		
	BG	WO-98/25604-A1	06-18-1998	Merck & Co., Inc.		
	BH	WO-02/06245-A1	01-24-2002	Synaptic Pharmaceutical Corporation		
	BI	WO-97/45415-A1	12-04-1997	Rotta Research Laboratorium S.P.A.		
	BJ	WO-2004/004714-A1	01-15-2004	Synaptic Pharmaceutical Corporation		
u	BK	WO-02/088089-A1	11-07-2002	Banyu Pharmaceutical Co., Ltd.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>3</sup>
	CA	Shiro Takekawa et al., "T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist", European Journal of Pharmacology 438 (2002) pp. 129-135.			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>3</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Chy</i>	Date Considered	12/15/05
--------------------	------------	-----------------	----------